Fireside Chat Date & Time:
Webcast Link: Register Here
A webcast of the fireside chat may also be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Investors and Media” tab. A replay of the fireside chat will be archived on the website for 90 days following the conclusion of the event.
About
Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In
Spero is also developing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.
Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.
For more information, visit https://sperotherapeutics.com.
Investor Relations Contact:
arr@lifesciadvisors.com
617-430-7577
Media Contact:
media@sperotherapeutics.com
Source:
2021 GlobeNewswire, Inc., source